Gynecology, the next generation of care; the next generation of value. Through collaboration with the gynecologic community, our goal is to use evidence-based solutions to reduce unnecessary variation to improve care quality and patient experience, and to lessen the cost of care.
Practice surgery anytime, anywhere with Touch Surgery
Touch Surgery is revolutionizing surgical education through a virtual training mobile platform. The app delivers cognitive training that has the potential to improve outcomes.
The following Gynecology Modules are COMING SOON: Gynecological Anatomy, Open Total Hysterectomy, Laparoscopic Total Hysterectomy & Total Vaginal Hysterectomy.
Hysterectomy Shared Decision Making: A Dialog Tool for the Patient & Doctor
The Hysterectomy Shared Decision Making tool is a conversation guide for gynecologists and patients that evaluates the reasons to perform a hysterectomy, various surgical approaches, and what to expect before, during, and after surgery.
Ethicon joins the SGO Industry Corporate Council
The Society of Gynecologic Oncology and its collaborative membership have been on a single pathway--help eradicate women’s cancer. Ethicon supports this very same mission by combining innovation with education and research for the needs of the gynecologic oncologist.
SURGICEL® Powder Absorbable Hemostat
Built to stop continuous, broad-surface oozing—fast1,2
Contains an aggregate of ORC fiber fragments that help control capillary, venous & small arterial hemorrhages.2,3 Proven bactericidal activity in vitro against all 5 hospital-acquired pathogens (MRSA, MRSE, VRE, PRSP, E.Coli).4-6 It’s unique structure of powder penetrates the surface of the blood to get to the source of bleeding.7,8
ENSEAL® X1 Large Jaw
Seal Better. Less bleeding,9 less thermal spread,10 and better ergonomics.11
ENSEAL® X1 with its adaptive tissue technology was significantly more hemostatic at the the distal tip9 & 41% less thermal spread compared to LigaSure Impact™.10 It’s 360° shaft rotation is designed to improve access to targeted tissue.11
HARMONIC® HD 1000i Shears
Unmatched precision, unparalleled strength, and optimized efficiency
Unique shape mimics a mechanical dissector* which may reduce the need to use a separate dedicated dissecting instrument.† It provided exceptional sealing strength as evidence by burst pressures of 150% compared to LigaSure™.‡ Strong tip grasping is designed to minimize tissue slippage and may aid in tissue manipulation & control.§
STRATAFIX™ Spiral Knotless Tissue Control Device
Provide more security, more consistency and more efficiency than traditional sutures12-19
Provide the wound-holding strength of interrupted suturing, with greater security and efficiency than continuous suturing.12-15,17,19-21 STRATAFIX™ Spiral reduced vaginal cuff dehiscence and bleeding compared to traditional methods of closure.¶ 22
DERMABOND® PRINEO® Skin Closure System
Greater skin holding strength than skin staples or subcuticular suture€,23
Provides a flexible microbial barrier with 99% protection in vitro for 72 hours against organisms commonly responsible for SSIs.¥,24 DERMABOND® PRINEO® distributes wound closure tension evenly along the incision and across the entire area of the incision.
Education & training
Offering a wide range of experiences with top-tier faculty around the country and resources to support you & your organization.
Research & evidence
Continuously evolving optimized patient outcomes through funding clinical research.
Access & Reimbursement
Helping patients gain access to the care they need with resources to inform on the clinical and economic value of gynecological surgery.
* Design Validation Study with surgeons (n=33) operating in simulated procedures in an animate porcine laboratory model.
† In a design validation study with surgeons (n=33) operating in simulated procedures in an animate porcine laboratory model (26/33)
‡ Based on a benchtop study with 5-7mm porcine carotid arteries. HARMONIC® HD (1878 mmHg) vs. LigaSure Maryland (1171 mmHg)and LigaSure Impact (1224 mmHg). (p<0.05)
§ Based on average device tip grasping force (distal 5 mm of the jaw).
¶ This study was performed with a device of similar material and anchor design to a STRATAFIX Spiral Device.
€ In an ex vivo study, more load in N was required to create a 3-mm gap between skin edges approximated with DERMABOND PRINEO System (22 cm) than with subcuticular 4-0 MONOCRYL® (poliglecaprone 25) Suture or PROXIMATE® Ethicon Endo-Surgery skin staples (P<.001).
¥ Staphylococcus epidermidis, Escherichia coli, Staphylococcus aureus, Pseudomonas aeruginosa, and Enterococcus faecium.
1. MacDonald MH. PSE Accession No. 15-0061. Pivotal Study Comparing Performance of SURGICEL® Powder Absorbable Hemostatic Powder to SURGICEL® Original Absorbable Hemostat in a Swine Acute Liver Abrasion Model. 2015.
2. MacDonald MH. PSE Accession No. 16-0006. Study Comparing Performance of SURGICEL® Powder Absorbable Hemostatic Powder to Marketed Competitive Powdered Topical Hemostats in a Swine Acute Liver Abrasion Model. 2016.
3. SURGICEL® Powder Absorbable Hemostat, Instructions for Use. Ethicon, Inc.
4. Spangler D, Rothenburger S, Nguyen K, Jampani H, Weiss S, Bhende S, In Vitro Antimicrobial Activity of Oxidized Regenerated Cellulose Against AntibioticResistant Microorganisms. Surgical Infections. 2003;4(3): 255-262.
5. Dineen P. The effect of oxidized regenerated cellulose on experimental infected splenotomies. J Surg Res 1977;23:114-116
6. SURGICEL® Absorbable Hemostat. Full Prescribing Information, Ethicon, Inc.
7. Wang A. 2-59164. Surface Energy/Tension Analysis among ORC Aggregate, ORC Fine Fiber and Arista – Project PIXIE.
8. Jiang T. Comparison of hemostatic performance of SURGICEL absorbable hemostatic products. 2007
9. Preclinical test of distal tip bleeding (ENSEAL® vs. Impact-LF4318) in thick porcine mesentery base (p<0.001).
10. Preclinical testing on porcine carotids (ENSEAL® vs Impact-LF4318) that measured mean max lateral thermal damage via histology (p=0.005).
11. Versus Ligasure Impact with only 180° rotation.
12 Moran ME, Marsh C, Perrotti M. Bidirectional-barbed sutured knotless running anastomosis v classic Van Velthoven suturing in a model system. J Endourol. 2007;21(10):1175-1178.
13. Vakil JJ, O’Reilly MP, Sutter EG, Mears SC, Belkoff SM, Khanuja HS. Knee arthrotomy repair with a continuous barbed suture: a biomechanical study. J Arthroplasty. 2011;26(5):710-713.
14. Eickmann T, Quane E. Total knee arthroplasty closure with barbed sutures. J Knee Surg. 2010;23(3):163-167.
15. Levine BR, Ting N, Della Valle CJ. Use of a barbed suture in the closure of hip and knee arthroplasty wounds. Orthopedics. 2011;34(9):e473-e475
16. Einarsson JI, Chavan NR, Suzuki Y, Jonsdottir G, Vellinga TT, Greenberg JA. Use of bidirectional barbed suture in laparoscopic myomectomy: evaluation of perioperative outcomes, safety, and efficacy. J Minim Invasive Gynecol. 2011;18 (1):92-95.
17. 100326296: Time Zero Tissue Holding - Competitive Claims Comparisons for STRATAFIX Knotless Tissue Control Devices vs Various Products. 2015.
18. Performance Testing of STRATAFIX SYMMETRIC PDS PLUS Size 0 & 1 Devices – Initiation Strength in Porcine Tissue. AST-2013-0603.
19. AST-2013-0056 Performance Testing of STRATAFIX Symmetric PDS Size2-0 suture device for Tissue Holding Strength with Multiple Incision Defects to Measure Gapping.
20. Ethicon study AST-2012-0331. Tissue gapping under tension of porcine cadaveric skin incisions closed with Stratafix Spiral in comparison to Monocryl in both interrupted and continuous stitching patterns. Approved on August 24, 2012.
21. Ethicon Performance Evaluation Memo AST-2012-0510. Performance Testing of STRATAFIX Symmetric Size 2-0 suture device for Tissue Holding Strength with an Incision Defect to Measure Gapping. Dated December 3, 2012.
22. Siedhoff MT, Yunker AC, Steege JF. Decreased incidence of vaginal cuff dehiscence after laparoscopic closure with bidirectional barbed suture. J Minim Invasive Gynecol. 2011;18: 218-223.
23. AST-2014-0246. Study to compare the tissue holding strength of DERMABOND® PRINEO® 22 cm Skin Closure System (DP22) to conventional wound closure techniques. Ethicon, Inc.
24. Su 06TR071 Study Report for in vitro evaluation of microbial barrier properties of DERMABOND ProTape. Ethicon, Inc
SURGICEL® Powder Absorbable Hemostat Essential Product Information
SURGICEL® Powder (oxidized regenerated cellulose) is used adjunctively in surgical procedures to assist in the control of capillary, venous, and small arterial hemorrhage when ligation or other conventional methods of control are impractical or ineffective.
- Do not inject or place SURGICEL® Powder into an open blood vessel.
- SURGICEL® Powder should not be used to control hemorrhage from large arteries.
- When SURGICEL® Powder is used to help achieve hemostasis in, around, or in proximity to foramina in bone, areas of bony confine, the spinal cord, or the optic nerve and chiasm, it must always be removed after hemostasis is achieved since it will swell and could exert unwanted pressure.
- SURGICEL® Powder should not be used for implantation in bone defects, such as fractures, since there is a possibility of interference with callus formation and a theoretical chance of cyst formation.
- Closing with SURGICEL® Powder in a contaminated wound without drainage may lead to complications and should be avoided.
- SURGICEL® Powder should not be impregnated with anti-infective agents or with other materials such as buffering or hemostatic substances.
- SURGICEL® Powder is dry and there may be difficulties in precise delivery under certain circumstances. Unintentional device placement may result in powder scattering and device migration that may increase the risk of adhesion formation.
- Although SURGICEL® Powder is bactericidal against a wide range of pathogenic microorganisms, it is not intended as a substitute for systemically administered therapeutic or prophylactic antimicrobial agents to control or to prevent postoperative infections.
- Do not attempt to trim the applicator tip.
SURGICEL® Powder should not be used in conjunction with autologous blood salvage circuits, because its fragments may pass through the transfusion filters of bloodscavenging systems.
Use only as much SURGICEL® Powder (oxidized regenerated cellulose) as is necessary and apply only where needed for hemostasis. Remove any excess before surgical closure in order to facilitate absorption and to minimize the possibility of foreign body reaction.
In urological procedures, minimal amounts of SURGICEL® Powder should be used and care must be exercised to prevent plugging of the urethra, ureter, or a catheter by dislodged portions of the product.
Since absorption of SURGICEL® Powder could be prevented in chemically cauterized areas, its use should not be preceded by application of silver nitrate or any other escharotic chemicals.
If SURGICEL® Powder is used temporarily to line the cavity of open wounds, it should be removed by irrigation with sterile water or saline solution after bleeding has stopped.
Precautions should be taken in otorhinolaryngologic surgery to ensure that none of the material is aspirated by the patient (e.g., controlling hemorrhage after tonsillectomy and controlling epistaxis).
This applicator tip is not intended for laparoscopic or other endoscopic use.
Paralysis and nerve damage have been reported when other SURGICEL® products were used around, in, or in proximity to foramina in bone, areas of bony confine, the spinal cord, and/or the optic nerve and chiasm.
Blindness has been reported in connection with surgical repair of a lacerated left frontal lobe when other SURGICEL® products were placed in the anterior cranial fossa (see WARNINGS and PRECAUTIONS).
Foreign body reactions have been reported with other products from the SURGICEL® Family of Absorbable Hemostats.
Burning has been reported when other SURGICEL® products were applied after nasal polyp removal. Headache, burning, stinging, and sneezing in epistaxis and other rhinological procedures, and stinging when SURGICEL® product was applied on surface wounds (varicose ulcerations, dermabrasions, and donor sites) have also been reported.
For more information and technical questions, call 1-800-795-0012.
GYNECARE INTERCEED® ABSORBABLE ADHESION BARRIER
Essential Product Information
GYNECARE INTERCEED Adhesion Barrier is indicated as an adjuvant in open (laparotomy) gynecologic pelvic surgery for reducing the incidence of postoperative pelvic adhesions after meticulous hemostasis is achieved consistent with microsurgical principles.
The use of GYNECARE INTERCEED Adhesion Barrier is contraindicated in the presence of frank infection. GYNECARE INTERCEED Adhesion Barrier is not indicated as a hemostatic agent. Appropriate means of achieving hemostasis must be employed.
The safety and effectiveness of GYNECARE INTERCEED Adhesion Barrier in laparoscopic surgery or any procedures other than open (laparotomy) gynecologic microsurgical procedures have not been established. Postoperative adhesions may be induced by GYNECARE INTERCEED Adhesion Barrier application if adjacent tissues (eg, ovary and tube) and structures are coapted or conjoined by the device, or if GYNECARE INTERCEED Adhesion Barrier is folded, wadded or layered. Care must be taken to apply GYNECARE INTERCEED Adhesion Barrier in single layers, interposed between adjacent anatomic structures at risk for adhesion formation.
Postoperative adhesions may occur in the presence of GYNECARE INTERCEED Adhesion Barrier if meticulous hemostasis is not achieved prior to application. As with all foreign substances, GYNECARE INTERCEED Adhesion Barrier should not be placed in a contaminated surgical site. Potentially contaminated surgical sites include hysterotomy following labor and/or prolonged rupture of membranes. The performance of GYNECARE INTERCEED Adhesion Barrier at potentially contaminated surgical sites has not been determined.
Use only a single layer of GYNECARE INTERCEED Adhesion Barrier, since multiple layers of packing or folding will not enhance the adhesion barrier characteristics and may interfere with the absorption rate of GYNECARE INTERCEED Adhesion Barrier. Care should be exercised in applying GYNECARE INTERCEED Adhesion Barrier to a pelvic organ not to constrict or restrict it. If the product comes in contact with blood prior to completing the procedure, it should be discarded, as fibrin deposition cannot be removed by irrigation and may promote adhesions formation.
Ectopic pregnancies have been associated with fertility surgery of the female reproductive tract. No data exist to establish the effect, if any, of GYNECARE INTERCEED Adhesion Barrier on the occurrence of ectopic pregnancies. No adequate studies have been conducted in women who have become pregnant within the first month after exposure to GYNECARE INTERCEED Adhesion Barrier. No teratogenic studies have been performed. Therefore, avoidance of conception should be considered during the first complete menstrual cycle after use of GYNECARE INTERCEED Adhesion Barrier. The safety and effectiveness of using GYNECARE INTERCEED Adhesion Barrier in combination with other adhesion prevention treatments have not been clinically established.
GYNECARE INTERCEED Adhesion Barrier is supplied sterile. As the material is not compatible with autoclaving or ethylene oxide sterilization, GYNECARE INTERCEED Adhesion Barrier must not be resterilized. Foreign body reactions may occur in some patients.
Interactions may occur between GYNECARE INTERCEED Adhesion Barrier and some drugs used at the surgical site. Pathologists examining sites of GYNECARE INTERCEED Adhesion Barrier placement should be made aware of its usage and of the normal cellular response to GYNECARE INTERCEED Adhesion Barrier ‘to facilitate proper evaluation of specimens'.
The type and frequency of adverse events reported are consistent with events typically seen following surgery. Postsurgical adhesions may occur in the presence of GYNECARE INTERCEED Adhesion Barrier.
For complete indications, contraindications, warnings, precautions, and adverse reactions, please reference full package insert.